To assess the relative bioavailability of LY03004 compared to Risperdal® Consta® at 25 mg following multiple intramuscular injections at steady-state;~To evaluate the safety and tolerability of LY03004 following repeated intramuscular injections~To evaluate the preliminary efficacy of LY03004 following repeated intramuscular injections
This study is to assess the bioavailability of LY03004 compared to Risperdal Consta as well as the evaluate the safety and tolerability and preliminary efficacy of LY03004 with repeat injections